21 completed, 9 terminated, 4 active not recruiting. 24 Phase 2, 9 Phase 1, 3 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 17, Terminated 5, Active not recruiting 2 |
| Phase 1 | 9 | Completed 5, Terminated 4 |
| Not applicable | 3 | Completed 2, Terminated 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Stage I Chronic Lymphocytic Leukemia: new trials by email Literature Review of Stage I Chronic Lymphocytic Leukemia trials Research Report on Stage I Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy Ibrutinib, Laboratory Biomarker Analysis - Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia | Phase 2 | Completed | Mayo Clinic | 35 | 2016-02-08 | 2026-09-25 |
| Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis Laboratory Biomarker Analysis, Lenalidomide, Pneumococcal 13-valent Conjugate Vaccine - Monoclonal B-Cell Lymphocytosis, Stage 0 Chronic Lymphocytic Leukemia | Phase 2 | Terminated | Mayo Clinic | 12 | 2015-06-11 | 2021-01-19 |
| Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma curcumin, cholecalciferol, laboratory biomarker analysis - Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma | Phase 2 | Completed | Paolo Caimi, MD | 35 | 2014-10-16 | 2024-04-12 |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL MOR00208, lenalidomide, Correlative Studies - Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 41 | 2014-01-17 | 2025-12-15 |
| Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Bendamustine Hydrochloride, Biospecimen Collection, Bone Marrow Aspiration - Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 547 | 2014-01-15 | 2026-10-22 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 49 | 2011-11-02 | 2026-05-27 |
| Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia Dasatinib, Laboratory Biomarker Analysis, Pharmacological Study - Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia | Phase 2 | Completed | OHSU Knight Cancer Institute | 19 | 2011-10-01 | 2021-04-08 |
| Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia alemtuzumab, ofatumumab, biopsy - Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | Northwestern University | 53 | 2011-06-01 | 2025-05-23 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant infection prophylaxis and management, laboratory biomarker analysis, flow cytometry - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Active not recruiting | City of Hope Medical Center | 153 | 2011-01-11 | 2026-10-22 | |
| Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia alemtuzumab, rituximab, PGG beta-glucan - B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Mayo Clinic | 22 | 2011-01-01 | 2020-06-23 |
| Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer massage therapy, questionnaire administration, quality-of-life assessment - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Not applicable | Completed | Wake Forest University Health Sciences | 80 | 2010-04-01 | 2018-07-02 |
| Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Alvocidib Hydrochloride, Cyclophosphamide, Diagnostic Laboratory Biomarker Analysis - Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 9 | 2010-04-01 | 2015-11-11 |
| Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Cyclophosphamide, Laboratory Biomarker Analysis, Ofatumumab - Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia | Phase 2 | Completed | Mayo Clinic | 82 | 2010-03-01 | 2018-09-18 |
| Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia lenalidomide, laboratory biomarker analysis, lymph node biopsy - B-cell Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Not applicable | Terminated | Roswell Park Cancer Institute | 8 | 2010-01-01 | 2016-06-30 |
| Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer rituximab, mycophenolate mofetil, tacrolimus - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Terminated | University of Nebraska | 20 | 2009-12-10 | 2023-09-06 |
| Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Fludarabine Phosphate, Cyclophosphamide, Rituximab - Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 40 | 2009-06-01 | 2020-02-25 |
| Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis - Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 418 | 2008-01-15 | 2023-05-22 |
Showing 20 of 34. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (34) · Lymphoma, B-Cell, Marginal Zone (11) · Lymphoma, Follicular (11) · Lymphoma, Large B-Cell, Diffuse (11) · Lymphoma, Mantle-Cell (11) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Burkitt Lymphoma (10) · Leukemia, Prolymphocytic (10) · Waldenstrom Macroglobulinemia (10) · Leukemia, Myeloid, Accelerated Phase (9) · Leukemia, Myeloid, Chronic-Phase (9) · Blast Crisis (8) · Congenital Abnormalities (8) · Hodgkin Disease (8) · Leukemia, Hairy Cell (8)
Chronic Disease (34) · Disease Attributes (34) · Hematologic Diseases (34) · Hemic and Lymphatic Diseases (34) · Immune System Diseases (34) · Immunoproliferative Disorders (34) · Leukemia, B-Cell (34) · Leukemia, Lymphoid (34) · Lymphatic Diseases (34) · Lymphoproliferative Disorders (34) · Neoplasms (34) · Neoplasms by Histologic Type (34) · Pathologic Processes (34) · Pathological Conditions, Signs and Symptoms (34) · Leukemia (32)
Rituximab (11) · fludarabine phosphate (8) · Cyclophosphamide (7) · Lenalidomide (6) · Flow Cytometry (4) · Mycophenolic Acid (4) · Tacrolimus (4) · alvocidib (4) · Alemtuzumab (3) · Biopsy (3) · Cyclosporine (3) · Whole-Body Irradiation (3) · Antilymphocyte Serum (2) · Busulfan (2) · CT-P10 (2)
National Cancer Institute (NCI) (14) · Fred Hutchinson Cancer Center (5) · Mayo Clinic (4) · City of Hope Medical Center (2) · Case Comprehensive Cancer Center (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · Ohio State University Comprehensive Cancer Center (1) · Paolo Caimi, MD (1) · Roswell Park Cancer Institute (1) · University of Chicago (1) · University of Nebraska (1) · Wake Forest University Health Sciences (1)
United States (34) · Canada (2) · Italy (1) · Sweden (1)
John Byrd (2) · Mazyar Shadman (2) · Ryotaro Nakamura (2) · Tait Shanafelt (2) · Ajay Gopal (1) · Ann Woolfrey (1) · Asher Chanan-Khan, M.D. (1) · Brenda Cooper, MD (1) · David Maloney (1) · Janet Tooze, PhD (1) · Jennifer A Woyach (1) · Jennifer Brown (1) · Jennifer Woyach, MD (1) · John C Byrd (1) · Joseph Flynn (1)
PMID 18698002, PMID 23547837, PMID 24431228, PMID 26853648, PMID 27118540, PMID 27570087, PMID 30501481, PMID 30562587, PMID 32499241, PMID 34274940, PMID 38215395, PMID 40720747
P30CA015704 (4), U10CA031946 (4), P30CA016058 (3), U01CA076576 (3), N01CM00070 (2), P30CA015083 (2), U10CA180821 (2), K23CA178183 (1), N01CM62201 (1), N01CM62202 (1), N01CM62207 (1), P01CA018029 (1), P01CA078902 (1), P01CA095426 (1), P30CA014236 (1)